OBJECTIVE: We investigated the anti-inflammatory activity of strontium ranelate (SR) in arthritis models. MATERIALS AND METHODS: Rats received 1 mg zymosan (Zy) or saline intra-articularly. Other groups were subjected to anterior cruciate ligament transection in the right knee, as an osteoarthritis (OA) model, or a sham procedure. Joint pain was assessed using the articular incapacitation and paw-pressure tests. Cell influx and cytokines were measured in joint exudates. TREATMENT: Groups received either SR (30-300 mg/kg per os) or saline. RESULTS: SR dose-dependently and significantly inhibited joint pain in both Zy and OA models, while not altering cell influx. Naloxone administration significantly reversed SR analgesia. SR significantly reduced levels of Interleukin-1β and tumor necrosis factor-α in Zy arthritis, whereas those of cytokine-induced neutrophil chemoattractant (CINC)-1 were not altered. CONCLUSIONS: SR provides analgesia in arthritis that is associated to inhibition of the release of inflammatory cytokines into inflamed joints. This effect is abrogated by administration of the opioid antagonist naloxone.
OBJECTIVE: We investigated the anti-inflammatory activity of strontium ranelate (SR) in arthritis models. MATERIALS AND METHODS:Rats received 1 mg zymosan (Zy) or saline intra-articularly. Other groups were subjected to anterior cruciate ligament transection in the right knee, as an osteoarthritis (OA) model, or a sham procedure. Joint pain was assessed using the articular incapacitation and paw-pressure tests. Cell influx and cytokines were measured in joint exudates. TREATMENT: Groups received either SR (30-300 mg/kg per os) or saline. RESULTS:SR dose-dependently and significantly inhibited joint pain in both Zy and OA models, while not altering cell influx. Naloxone administration significantly reversed SRanalgesia. SR significantly reduced levels of Interleukin-1β and tumor necrosis factor-α in Zy arthritis, whereas those of cytokine-induced neutrophil chemoattractant (CINC)-1 were not altered. CONCLUSIONS:SR provides analgesia in arthritis that is associated to inhibition of the release of inflammatory cytokines into inflamed joints. This effect is abrogated by administration of the opioid antagonist naloxone.
Authors: J Y Reginster; E Seeman; M C De Vernejoul; S Adami; J Compston; C Phenekos; J P Devogelaer; M Diaz Curiel; A Sawicki; S Goemaere; O H Sorensen; D Felsenberg; P J Meunier Journal: J Clin Endocrinol Metab Date: 2005-02-22 Impact factor: 5.958
Authors: A C R de Melo Leite; M A A Teotonio; V C C Girão; M M de Lima Pompeu; R de Melo Nunes; T M Cunha; A C M D Pinto; F de Queiroz Cunha; F A C Rocha Journal: Osteoarthritis Cartilage Date: 2014-07-31 Impact factor: 6.576
Authors: Thiago A Rodrigues; Abner de Oliveira Freire; Heetor C O Carvalho; Gyl E B Silva; José W Vasconcelos; Rosane N M Guerra; Maria do Socorro de Sousa Cartágenes; João B S Garcia Journal: Front Pharmacol Date: 2018-09-19 Impact factor: 5.810